Moderna Shares Surge Over 12% on Melanoma Vaccine Data and Upcoming Pipeline Updates

SentiSense · Published Sep 21, 2026, 11:45 AM ET · Updated Sep 28, 2026, 2:45 AM ET

Moderna rose 12.27% on September 21, 2026, touching a 52-week high of $176.75, after its Phase 3 INTerpath-001 melanoma study with Merck's Keytruda won a Presidential Symposium slot at ESMO on October 24. No new efficacy data was released; Merck and BioNTech gained about 2% each, and the consensus price target of about $120 remains well below the stock.

MRNA jumped 12.27% on Monday, September 21, and touched a 52-week high of $176.75, according to Investing.com. The catalyst was scheduling news rather than new data: the Phase 3 INTerpath-001 trial of intismeran autogene with MRK's Keytruda in resected melanoma was awarded a Presidential Symposium slot at the ESMO Congress in Madrid, with the presentation set for October 24.

24/7 Wall St. reported that no new efficacy data was released Monday and that the symposium slot itself was the signal. The 1,137-patient trial compares the combination against Keytruda alone. Partner Merck rose 1.79% and BioNTech 2.02% on the day, which 24/7 Wall St. read as a Moderna-specific rerating rather than a broad mRNA oncology move.

Other support came from analysts and financing. Investing.com cited an Argus upgrade to Buy with a $180 target and the FDA approval of Moderna's updated 2026-2027 COVID-19 vaccines, and noted a late-August convertible note offering that gave the company more room to fund oncology work. The counterweight is valuation: TIKR put the consensus mean price target around $120, roughly 31% below where the stock traded after the move.

The next hard catalyst is the October 24 ESMO presentation, where the market will see whether the Phase 3 results justify the rerating. With the stock above most analyst targets, the readout carries meaningful downside risk if the data disappoint.